ADVERSE TRANSFUSION REACTIONS
A transfusion should be stopped immediately whenever a transfusion reaction is suspected and an investigation performed according to institution procedures. Should there be an issue, where after investigation, the reaction needs to be reported to Vitalant due to an attribute specific to the donor or the processing of the blood product (e.g., potential bacterial contamination of the component), report the information using the AABB Report of Adverse Reaction Form. The tables below list symptoms associated with types of reactions.
If an adverse reaction occurs
We need your help to report promptly any reactions that may be due to an attribute specific to the donor or processing of the blood or blood components. Examples of such adverse events include:
- Sepsis (due to bacterial contamination of blood components)
- TRALI (due to HLA antibodies in donated blood)
- Infection (due to window-period infections or pathogens for which there are no tests)
In all cases, timely reporting is vital, so that we may prevent the transfusion of other components from the same donor(s) or donation(s), if needed. You will report recipient adverse events to us and any other blood supplier who may provide blood or blood components to your facility using this NEW form.
Please note that for transfusion-associated infections other than septic bacterial reactions, you will need to continue to use Form BS 314.
Understanding the incidence of adverse reactions associated with transfusion is essential to continuously improve the safety of the blood supply. Our goal is aligned with yours. We want to provide patients with the products they need when they need it and with the desired outcome. Our investigations into adverse patient reactions allow us to evaluate and follow up with donors, as appropriate, to determine their future eligibility as a community blood donor. Additionally, components made from the blood of implicated donors may need to be quarantined and other recipients may need to be notified.
In order to expedite our investigation we ask that you please provide complete clinical information; it is essential to our evaluation. You can find all the forms you need here on our website. Frequently asked questions are included on the new AABB form.
Vitalant has information regarding transfusion-associated risks including the incidence of some transfusion adverse reactions based on active surveillance studies and incidence of residual risk for transfusion transmitted infections based on current screening practices. We hope that you consider these statistics as a benchmark for your institution. Case definitions of transfusion adverse reactions are described in the CDC’s National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol.
NOTE: The Code of Federal Regulations, Title 21, Section 606.170, and the AABB Standards for Blood Banks and Transfusion Services, Standard 7.5, address the requirements for the recognition, evaluation, and reporting of suspected adverse events in recipients related to the transfusion of blood components and to the use of tissue or derivatives supplied by all blood collection agencies and blood product manufacturers.
If you have any questions or comments, please call 1-800.811.2581. Thank you for your continued support of Vitalant and our efforts to ensure the safety of our blood supply.